For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease
In the full population of ASCENT
Median OS of ~1 year with TRODELVY1
TRODELVY significantly improved survival vs single-agent chemotherapy1,2
Kaplan-Meier estimates of median OS (full population)
Reproduced with permission from Bardia et al, N Engl J Med, 2021; copyright Massachusetts Medical Society.
2L=second line; brain-met=brain metastases; CI=confidence interval; HR=hazard ratio; OS=Overall Survival.
Please see primary analysis (brain-met negative) and brain-met positive data below.
In the primary analysis (brain-met negative) population of ASCENT
Median OS of 1 year with TRODELVY2
Statistically significant results were demonstrated vs patients treated with single-agent chemotherapy across both the primary analysis and full populations1,2
Secondary endpoint: Kaplan-Meier estimates of median OS (brain-met negative population)2
Reproduced with permission from Bardia et al, N Engl J Med, 2021; copyright Massachusetts Medical Society.
Please see full population data above and brain-met positive data below.
Exploratory findings in previously treated, stable brain-met positive patients1
Median OS
6.8 months for TRODELVY (95% CI: 4.7–14.1) vs 7.4 months with single-agent chemotherapy (95% CI: 4.7–11.1); HR: 0.87 (95% CI: 0.47–1.63)
In the ASCENT trial:
- MRI was required prior to enrollment to determine existence or extent of known or suspected brain metastases
- Patients with brain metastases were allowed to enroll up to a predefined maximum of 15% of study patients
- 12% of patients had baseline brain metastases previously treated and stable (n=61; 32 on TRODELVY arm and 29 on single-agent chemotherapy arm)
MRI=magnetic resonance imaging.
In a post-hoc subgroup of the ASCENT trial of patients without brain metastases
Median OS of TRODELVY vs 4 single-agent chemotherapies in the comparator arm3*
88% of patients in the ASCENT trial were brain-met negative, and OS results of this sub-analysis were consistent with the ASCENT findings1-3
In this post-hoc subgroup analysis of ASCENT, Kaplan-Meier estimates of median OS by BICR based on RECIST 1.1 criteria (brain-met negative population)3
*Limitation: These results are from a post-hoc subgroup analysis of the phase 3 ASCENT trial. The single-agent chemotherapy arms were not powered for statistical analysis or designed to compare against individual agents and should be considered descriptive only. Therefore, the results require cautious interpretation and could represent chance findings.
BICR=blinded, independent, central review; RECIST=Response Evaluation Criteria in Solid Tumors.
Safety findings from this post-hoc subgroup analysis of ASCENT3
| Single-agent chemotherapy (n=224) | |||||||
|---|---|---|---|---|---|---|---|
| TRODELVY (n=258) |
Eribulin (n=123) |
Vinorelbine + capecitabine + gemcitabine (n=101) |
|||||
| Treatment-related adverse eventsa | All grades (%) |
Grade 3/4 (%) |
All grades (%) |
Grade 3/4 (%) |
All grades (%) |
Grade 3/4 (%) |
|
| Neutropeniab | 63 | 51 | 39 | 31 | 48 | 36 | |
| Anemiab | 34 | 8 | 23 | 2 | 26 | 8 | |
| Leukopeniab | 16 | 10 | 11 | 5 | 11 | 6 | |
| Febrile neutropenia | 6 | 6 | 2 | 2 | 2 | 2 | |
| Diarrhea | 59 | 10 | 8 | 0 | 17 | 1 | |
| Nausea | 57 | 3 | 29 | 1 | 23 | 0 | |
| Vomiting | 29 | 1 | 11 | 1 | 9 | 0 | |
| Alopecia | 46 | 0 | 25 | 0 | 4 | 0 | |
| Fatigue | 45 | 3 | 31 | 5 | 30 | 6 | |
- Discontinuation rates due to treatment-emergent adverse events for TRODELVY, eribulin, vinorelbine, capecitabine, and gemcitabine were 5%, 2%, 10%, 7%, and 9%, respectively
- 1 treatment-related death was reported for the single-agent chemotherapy arm (eribulin; neutropenic sepsis) and none with TRODELVY
aPatients may report more than 1 event per preferred term. Adverse events (AEs) were coded using MedDRA v22.1, and AE severity was graded per NCI CTCAE v4.03.
bNeutropenia contains combined preferred terms of neutropenia and decreased neutrophil count, anemia contains combined preferred terms of anemia and decreased hemoglobin, and leukopenia combines preferred terms of leukopenia and decreased white blood cell count; all are counted once for each preferred term.
MedDRA=Medical Dictionary for Regulatory Activities; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.
References: 1. TRODELVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; June 2022. 2. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529-1541. 3. O’Shaughnessy J, Punie K, Oliveira M, et al. Assessment of sacituzumab govitecan vs treatment of physician’s choice cohort by agent in the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer. Poster presented at: Virtual American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021.
TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
- Severe or life-threatening neutropenia may occur. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis. Initiate anti-infective treatment in patients with febrile neutropenia without delay.
- Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed. Administer atropine, if not contraindicated, for early diarrhea of any severity. At the onset of late diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤Grade 1 and reduce subsequent doses.
CONTRAINDICATIONS
- Severe hypersensitivity reaction to TRODELVY.
WARNINGS AND PRECAUTIONS
Neutropenia: Severe, life-threatening, or fatal neutropenia can occur and may require dose modification. Neutropenia occurred in 61% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 47% of patients. Febrile neutropenia occurred in 7%. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 on Day 1 of any cycle or neutrophil count below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever.
Diarrhea: Diarrhea occurred in 65% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 12% of patients. One patient had intestinal perforation following diarrhea. Neutropenic colitis occurred in 0.5% of patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to ≤Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.
Hypersensitivity and Infusion-Related Reactions: Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with TRODELVY. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 37% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.3%. The incidence of anaphylactic reactions was 0.3%. Pre-infusion medication is recommended. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Medication to treat such reactions, as well as emergency equipment, should be available for immediate use. Permanently discontinue TRODELVY for Grade 4 infusion-related reactions.
Nausea and Vomiting: Nausea occurred in 66% of all patients treated with TRODELVY and Grade 3 nausea occurred in 4% of these patients. Vomiting occurred in 39% of patients and Grade 3-4 vomiting occurred in 3% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.
Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with TRODELVY. The incidence of Grade 3-4 neutropenia was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 25% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 11% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.
Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.
ADVERSE REACTIONS
In the ASCENT study (IMMU-132-05), the most common adverse reactions (incidence ≥25%) were fatigue, neutropenia, diarrhea, nausea, alopecia, anemia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.
DRUG INTERACTIONS
UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with TRODELVY.
UGT1A1 Inducers: Exposure to SN-38 may be substantially reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with TRODELVY.
Please see full Prescribing Information, including BOXED WARNING.